Moderna की mRNA मौसमी फ्लू वैक्सीन देर‑स्तर के परीक्षण में पारंपरिक शॉट से बेहतर – FDA समीक्षा लंबित
40,000 से अधिक 50+ आयु के वयस्कों पर किए गए देर‑स्तर के परीक्षण में दिखा कि Moderna की mRNA‑आधारित मौसमी फ्लू वैक्सीन GSK की स्टैंडर्ड‑डोज़ शॉट से 26.6% अधिक प्रभावी थी। यू.एस. FDA आवेदन की समीक्षा कर रहा है, और निर्णय 5 अगस्त 2026 तक अपेक्षित है, जबकि एंटी‑वैक्सीन कार्यकर्ता Robert F. Kennedy Jr. ने अतिरिक्त जांच की म…
In a large international trial involving more than 40,000 adults aged 50 years and older, Moderna 's seasonal influenza vaccine demonstrated superior efficacy compared with the standard‑dose vaccine from GSK . The study, published in the New England Journal of Medicine , reported a 26.6% higher effectiveness, surpassing the pre‑specified goal of non‑inferiority. Key Developments The mRNA vaccine, designated mRNA technology , showed a modest increase in mild‑to‑moderate side‑effects such as injection‑site pain, fatigue, headache and muscle aches. Severe adverse events were comparable between groups (2.2% with the mRNA shot vs 1.9% with the standard dose). The U.S. FDA rejected the initial application in February, citing the need for comparison with a high‑dose flu vaccine for the ≥65 age group. After discussions, the agency accepted an amended filing, with a commitment that Moderna will conduct an additional study in older adults post‑approval. Regulatory reviews are also underway in the European Union, Canada and Australia. Important Facts Trial size: >40,000 participants, ages 50 +. Efficacy gain: 26.6% over standard‑dose GSK vaccine. Safety: Mostly mild‑to‑moderate reactions; severe events balanced across arms. Decision deadline: August 5, 2026 (FDA). Potential first mRNA seasonal flu vaccine approved in the United States. Anti‑vaccine activist Robert F. Kennedy Jr. has called for heightened scrutiny of the technology. UPSC Relevance The episode illustrates the intersection of science, public health policy, and regulatory governance—core themes for GS 3 (Health, Science & Technology) and GS 4 (Ethics, Govern
Quick Reference
Key Insight
US FDA poised to approve first mRNA flu vaccine, reshaping global vaccine policy
Key Facts
- Trial involved >40,000 adults aged 50 years and above across multiple countries.
- Moderna’s mRNA flu vaccine showed 26.6% higher efficacy than GSK’s standard‑dose vaccine.
- Severe adverse events were similar: 2.2% (mRNA) vs 1.9% (standard) with mainly mild‑to‑moderate reactions.
- FDA rejected the initial filing in February 2026; an amended application now has a decision deadline of 5 August 2026.
- The vaccine could become the first mRNA seasonal influenza shot approved in the United States, with reviews also underway in the EU, Canada and Australia.
- Activist Robert F. Kennedy Jr. has called for heightened scrutiny, highlighting the role of public discourse in vaccine policy.
Background
The trial underscores how emerging mRNA technology is being evaluated against conventional vaccines, a key issue under GS‑3 (Health, Science & Technology). It also illustrates the regulatory role of agencies like the US FDA and the influence of civil society, relevant to GS‑4 (Governance, Ethics) and India's own drug‑approval framework.
UPSC Syllabus
- Prelims_CSAT — Decision Making
Mains Angle
GS‑3: Discuss the implications of approving mRNA‑based seasonal influenza vaccines for India’s public‑health strategy. Possible question – ‘Evaluate the challenges and opportunities of adopting mRNA technology for seasonal vaccines in India.’